Tonsillectomy Delays Progression of Advanced IgA Nephropathy to End-Stage Kidney Disease

REFERENCES

• D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–727.
   PubMedGoogle Scholar
• Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide: A neglected disease in the United States? Am J Med. 1988;84:129–132.
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Yokoyama H, Sato H, . Committee for Standardization of Renal Pathological Diagnosis and Working Group for Renal Biopsy Database, Japanese Society of Nephrology, Tokyo, Japan. Japan Renal Biopsy Registry: The first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011;15:493–503.
   PubMed Web of Science ®Google Scholar
• Floege J. The pathogenesis of IgA nephropathy: What is new and how does it change therapeutic approaches? Am J Kidney Dis. 2011; 58:992–1004.
   Google Scholar
• Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. Am J Nephrol. 2009;30:315–322.
   PubMed Web of Science ®Google Scholar
• Zhou YH, Tang LG, Guo SL, . Steroids in the treatment of IgA nephropathy to the improvement of renal survival: A systematic review and meta-analysis. PLoS One. 2011;6:e18788.
   Google Scholar
• Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–1583.
   PubMed Web of Science ®Google Scholar
• Coppo R, Peruzzi L, Amore A, . IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–1888.
   Google Scholar
• Xie Y, Nishi S, Ueno M, . The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–1867.
   PubMed Web of Science ®Google Scholar
• Akagi H, Kosaka M, Hattori K, . Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl. 2004;Suppl. 555:38–42.
   Google Scholar
• Komatsu H, Fujimoto S, Hara S, . Multivariate analysis of prognostic factors and effect of treatment in patients with IgA nephropathy. Ren Fail. 2005;27:45–52.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tang Z, Wang Q, . Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007;27:170–175.
   PubMed Web of Science ®Google Scholar
• Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;51:147–152.
   PubMed Web of Science ®Google Scholar
• Piccoli A, Codognotto M, Tabbi MG, Favaro E, Rossi B. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant. 2010;25:2583–2589.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Fujimoto S, Sato Y, . “Point of no return (PNR)” in progressive IgA nephropathy: Significance of blood pressure and proteinuria management up to PNR. J Nephrol. 2005;18:690–695.
   PubMed Web of Science ®Google Scholar
• Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Disease. 2nd ed., Tokyo: Igaku-Shoin; 1995:4–20.
   Google Scholar
• Koyama A, Igarashi M, Kobayashi M, . Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–532.
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Nitta K, . Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50.
   PubMedGoogle Scholar
• Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003;7:93–97.
   Google Scholar
• Bene MC, Hurault De Ligny B, Kessler M, Faure GC. Confirmation of tonsillar anomalies in IgA nephropathy: A multicenter study. Nephron. 1991;58:425–428.
   PubMed Web of Science ®Google Scholar
• Bene MC, Hurault Ligny B, Kessler M, Foliguet B, Faure GC. Tonsils in IgA nephropathy. Contrib Nephrol. 1993;104:153–161.
   PubMedGoogle Scholar
• Barratt J, Smith AC, Feehally J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton). 2007;12:275–284.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Seki G, Someya T, Nagata M, Fujita T. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin Dev Immunol. 2011;2011:470803.
   Google Scholar
• Novak J, Moldoveanu Z, Julian BA, . Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: Role of mucosal immune system. Adv Otorhinolaryngol. 2011;72:60–63.
   PubMedGoogle Scholar
• Itoh A, Iwase H, Takatani T, . Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant. 2003;18:1108–1114.
   PubMedGoogle Scholar
• Suzuki Y, Tomino Y. Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: Insights from animal models. Semin Nephrol. 2008;28:66–77.
   PubMed Web of Science ®Google Scholar
• van den Wall Bake AW, Daha MR, Evers-Schouten J, van Es LA. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: Evidence for the bone marrow as the source of mesangial IgA. Am J Kidney Dis. 1988;12:410–414.
   PubMed Web of Science ®Google Scholar
• van den Wall Bake AW, Daha MR, Radl J, . The bone marrow as production site of the IgA deposited in the kidneys of patients with IgA nephropathy. Clin Exp Immunol. 1988;72:321–325.
   PubMedGoogle Scholar
• Komatsu H, Fujimoto S, Hara S, . Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy. Am J Nephrol. 2009;30:19–25.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen J, Wang Y, Chen Y, Wang L, Lv Y. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26:1923–1931.
   PubMed Web of Science ®Google Scholar
• Kennoki T, Ishida H, Yamaguchi Y, Tanabe K. Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation. 2009;88:935–941.
   Google Scholar
• Ushigome H, Suzuki T, Fujiki M, . Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation. Clin Transplant. 2009;23(Suppl. 20):17–22.
   PubMedGoogle Scholar
• Tsuchiya T, Ito S, Yamaguchi Y, Moriyama Y, Ehara H, Deguchi T. Tonsillectomy and steroid pulse therapy for recurrent IgA nephropathy in renal allograft. Clin Nephrol. 2010;73:68–71.
   Google Scholar
• Hotta O, Miyazaki M, Furuta T, . Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–743.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: A controlled study. Clin J Am Soc Nephrol. 2008;3:1301–1307.
   Google Scholar